Roche Holdings AG (OTC:RHHBY) reported fiscal 2025 sales of 61.5 billion Swiss Francs (around $76.96 billion), up 7% (+2% in CHF) due to strong demand for pharmaceutical products and diagnostic solutions.
Core operating profit increased by 13% (5% in CHF) to CHF 21.8 billion, driven by higher sales and efficiency gains.
Core EPS increased 11% (+4% in CHF) to CHF 19.46 ($24.35).
Segment Performance
Sales in the Pharmaceuticals Division increased by 9% (3% in CHF) to CHF 47.7 billion, with medicines for severe diseases continuing their strong growth.
The top five growth drivers – Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo – achieved total sales of CHF 21.4 billion, an increase of CHF 3.2 billion (CER) compared to 2024.
Ocrevus sales were up 9% to CHF 7.01 billion, Hemlibra sales jumped 11% to CHF 4.75 billion, Vabysmo sales increased 12% to CHF 4.10 billion, Xolair sales were up 32% to CHF 3.07 billion, and
Phesgo revenues rose 48% to CHF 2.44 billion.
Sales of products with expired patents – Avastin (various types of cancer drug), Herceptin (breast and gastric cancer), MabThera/Rituxan (blood cancer, rheumatoid arthritis), Esbriet (lung disease), Lucentis (severe eye diseases), and Actemra/RoActemra (rheumatoid arthritis) – decreased by a combined CHF 0.7 billion (CER).
The Diagnostics Division’s sales increased by 2% (-3% in CHF) to CHF 13.8 billion as growth in demand for pathology and molecular solutions more than offset the impact of healthcare pricing reforms in China.
Roche CEO Thomas Schinecker on Thursday commented, “2025 was a strong year for Roche, reflecting our continued focus on operational and R&D excellence.”
“We are also setting new standards in diagnostics: our next-generation sequencing technology, which will be launched this year, decoded an entire human genome in less than four hours,” Schinecker added.
Outlook for 2026
Roche expects an increase in sales in the mid single-digit range (CER). Core earnings per share are targeted to develop in the high single-digit range (CER).
Dividend Increase
Roche expects to increase its dividend in Swiss francs. The board proposed a dividend increase to CHF 9.80 per share and a non-voting equity security. If approved by shareholders, this would be the 39th consecutive dividend increase.
RHHBY Price Action: Roche Holding shares were up 2.79% at $55.91 at the time of publication on Thursday. The stock is approaching its 52-week high of $57.29, according to Benzinga Pro data.
Photo by OleksSH via Shutterstock
Recent Comments